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http://dx.doi.org/10.1016/j.kjms.201Abstract Alpha-fetoprotein is a well-known tumor marker in the screening and follow-up of
hepatocellular carcinoma. In Taiwanese society, a high prevalence of hepatitis and hepatoma
and elevation of alpha-fetoprotein associated with liver function impairment usually suggested
clinics undertake further examination for liver or genital tumor. We report the case of 45-year-
old man who was found to have an alpha-fetoprotein-producing esophageal adenocarcinoma
with an initial presentation of liver function impairment and rapid elevation of alpha-
fetoprotein. Esophageal cancer was diagnosed via endoscope and a biopsy proved the presence
of adenocarcinoma. A small endoscopic biopsy specimen failed to identify the alpha-
fetoprotein positive tumor cell. Esophagectomy was performed and histopathological study
of surgical specimen revealed grade II adenocarcinoma with regional metastatic lymphadenop-
athy. Immunohistochemical study was focal positive for alpha-fetoprotein. Serum alpha-
fetoprotein declined transiently after esophagectomy and fluctuation of alpha-fetoprotein
level was noted during the treatment with adjuvant chemotherapy. Finally, 19 months after
the operation, the patient died due to multiple organ metastases with multiple organ failure.
Thus, a small specimen for upper endoscopy may not be sufficient in the presence of alpha-
fetoprotein-producing adenocarcinoma. Monitoring of serum alpha-fetoprotein may be useful
in the evaluation and follow-up of esophageal alpha-fetoprotein-producing adenocarcinoma.
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Alpha-fetoprotein and esophageal adenocarcinoma 107IntroductionFigure 1. Barium esophagogram showed a polypoid filling
defect in the distal esophagus and central depression was
noted (arrow). Mild contour irregularity and rigidity was also
identified at the esophagusecardiac junction.
Figure 2. Upper endoscopy showed a polypoid lesion with
fragility in the lower third of the esophagus. Mild lumen nar-
rowing was also noted.In Taiwan, an area with high prevalence of hepatocellular
carcinoma, elevation of alpha-fetoprotein (AFP) in cases
with abnormal level of liver enzymes usually advocate
clinicians to do more examinations for liver or genital
tumors. Increasing serum AFP that is associated with
malignant neoplasm is well-known in cases of hepatocel-
lular carcinoma, yolk sac tumor and other malignancies
including carcinoma of the stomach, gallbladder, lung,
urinary tract, pancreas and genital organs [1e8]; however,
there are few reports of esophageal cancer expressing AFP.
This case reports a rare AFP -producing adenocarcinoma
and we briefly review the published case series.
Case report
A 45-year-old man had a history of poliomyelitis with lower
leg muscular atrophy, essential hypertension, hyperlipid-
emia and fatty liver. He had taken regular medication
prescribed by local clinics for hypertension for 4 years. He
received a health work-up and liver function impairment
was evident. He was referred to our department for further
evaluation of hepatitis. The patient suffered no discomfort
except for dysphagia with solid food, which had been noted
in past month. Neither body weight loss nor abdominal pain
was mentioned. There were no obvious physical findings
except for muscular atrophy and scoliosis due to
poliomyelitis.
Our initial examination showed alanine aminotrans-
ferase 194 IU/L (normal range,10e40 IU/L), aspartate
aminotransferase 99 IU/L (normal range, 10e42 IU/L),
serum hepatitis B surface antigen negative, anti-hepatitis
C virus negative, antinuclear antibody negative and AFP
28.6 IU/ml (normal range, <9.0 IU/ml). Abdominal ultra-
sound study showed fatty liver and the tentative diagnosis
was non-alcoholic steatosis hepatitis.
Due to the unusual elevation of AFP, we checked his AFP
level 2 months later and it had increased to 171.8 IU/ml.
Further serum biochemical study showed hemoglobin
12.2gm/dl (normal range, 14e17.5 gm/dl), albumin 4.71
gm/dl (normal range, 3.5e5.0 gm/dl), alkaline phosphatase
88 IU/L (normal range, 32e92 IU/L), r-glutamyl trans-
peptidase 49 IU/L(normal range,7e64 IU/L) and stool
routine occult blood positive. Serum tumor marker studies
showed squamous cell carcinoma 0.4 ng/ml (normal range,
<1.5 ng/ml), carbohydrate-19-9 antigens 71.5 U/ml
(normal range, <37 U/ml) and carcinoembryonic antigen
1.13 ng/ml (normal range, <5 ng/ml).
An esophagogram was arranged and showed a polypoid
filling defect in the distal esophagus with central depres-
sion. Mild contour irregularity and rigidity was also noted at
the esophagusecardiac junction (Fig. 1). Upper endoscope
revealed a polypoid lesion in the lower esophagus at
a distance of 36 cm from the incisor just above the
esophagealecardiac junction with easy fragility and mild
lumen narrowing (Fig. 2). Endoscopic biopsy was performed
and histological examination showed a grade II adenocar-
cinoma. However, endoscope biopsy specimen was too
small to show immunohistochemical study of AFP positive
(Data not shown). Abdomen computed tomographyrevealed low esophageal invasion to adventitia and exten-
sion to the adjacent gastric cardiac portion. Metastatic
lymphadenopathy in the para-aortic region and perigastric
region was also noted. Image staging therefore classes the
adenocarcinoma as being stage IV (T3N1M1a), see Fig. 3.
Following patient request and a fine performance status,
the patient received esophagectomy, lymphadenectomy
and partial gastrectomy with reconstruction. The tumor
was 4  3  1.5 cm in size. The tumor bulk was located
0.2 cm above the gastroesophageal junction. It extended to
the adjacent stomach and deep into the adventitia of the
esophagus. Microscopic examination showed grade II
adenocarcinoma with adventitia invasion. Lymphovascular
invasion and perineural invasion were also noted. Immu-
nohistochemical study was focal positive for AFP stain
(Fig. 4). Metastatic lymphadenopathy with adenocarcinoma
Figure 3. Abdominal computed tomography revealed
annular wall thickening with a blurred adventitia margin in the
lower esophagus and the soft tissue mass lesion was downward
to the cardiac portion. Metastatic lymphadenopathy was noted
(arrow).
108 Y.-Y. Chen et al.was also noted. Surgical staging was stage IV (T3N1M1a).
Serial examinations of AFP showed rapid elevation of AFP
before the operation and an abrupt decrease after tumor
resection (see Fig. 5).Figure 4. Histological appearance of the surgical specimen f
Immunochemistry stain with alpha-fetoprotein was focal positive wIn the following 8 months, the patient received 16
courses of adjuvant chemotherapy with cisplatin plus high-
dose 5-fluorouracil. The image study with positron emission
tomography, however, revealed multiple intensive foci in
lymph nodes in the subclavian and middle thoracic para-
esophageal region. As the patient appeared to be suffering
from a relapse, he received a further nine courses of
chemotherapy with oxaliplatin plus high-dose 5-fluorouracil
and radiotherapy in the following 6 months. Despite this,
peritoneal carcinomatosis with massive ascites, liver
metastasis and right pleural metastasis were encountered
in the following image study. AFP had increased to a level of
12267.0 ng/ml 14 months after the operation. Although the
patient received another four courses of irinotecan plus
carboplatin, the disease progressed rapidly. Nineteen
months after the initial operation, the patient expired due
to multiple organ failure.Discussion
AFP is the fetal globulin that is synthesized by the fetal liver
and yolk sac from the sixth week of gestation [9]. AFP has
a molecular weight of 70,000 Daltons, consisting of a single
peptide chain and containing about 4% carbohydrate. After
birth, the level of AFP gradually decreases to a normal adult
range of 10e20 IU/ml within a few weeks or months [9].
AFP is a useful tumor marker for hepatocellular carci-
noma and yolk sac tumor. Elevation of serum AFP has been
reported in patients with other malignancies including
stomach, gallbladder, lung, urinary tract, pancreas and
genital organ cancers. McIntire et al. reported thatrom the esophageal caner showed tubular adenocarcinoma.
ith alpha-fetoprotein in cytoplasm (arrows).
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Figure 5. The alpha-fetoprotein level dropped immediately
after esophagectomy (arrow). It increased again with tumor
recurrence.
Alpha-fetoprotein and esophageal adenocarcinoma 109elevation of serum AFP had been observed in gastrointes-
tinal neoplasm: 15% of 95 patients with gastric carcinoma,
3% of 191 patients with colorectal carcinoma, 24% of 45
patients with pancreatic carcinoma, 25% of eight patients
with biliary tract carcinoma and 70% of 73 patients with
hepatocellular carcinoma had elevated serum AFP [10].
Esophageal cancer and small intestine neoplasm had the
lowest percentage of elevated AFP [10]. Overall, AFP was
not a good parameter for the screening of gastrointestinal
neoplasm or metastatic liver diseases [11].
Most esophageal adenocarcinomas were located over the
lower third of the esophagus and were related to Barrett’s
esophagus. Few case reports have noted AFP-producing
esophageal cancer. Some cases of AFP-producing esopha-
geal adenocarcinomawere derived fromBarrett’s esophagus
and they could also be regarded as closely resembling AFP-
producing gastric carcinomas.
Some carcinomas with high levels of serum AFP contained
cells resembling a hepatic cell classified as hepatoid adeno-
carcinoma. In comparison with hepatoid adenocarcinoma,
AFP-producing carcinomas with no histologic characteristics
of hepatocellular carcinomas are termed AFP-producing
adenocarcinomas [12].Table 1 Summary of hepatoid carcinoma and alpha-fetoprotein
Ref. Age Sex Tumor name BE
[13] 80 F Hepatoid þ Di
[14] 44 F Hepatoid þ Di
[15] 47 M Hepatoid þ Di
[16] 56 M Hepatoid ? ??
[17] 76 M Hepatoid þ Al
[18] 80 M AFP-producing ? Di
[19] 59 M AFP-producing þ Di
[20] 51 M AFP-producing  Di
[21] 69 M AFP-producing ? Al
*Alive at the follow-up of 2 months; #alive at the follow-up of 6 monPrimary gastrointestinal hepatoid adenocarcinoma is
very rare and cases mostly arise from the gastric epithe-
lium. This neoplasm has a poor prognosis, readily metas-
tasizes to the liver, and is frequently found at an advanced
stage of disease. To the best of our knowledge, there have
been only nine reported cases of AFP-producing esophageal
adenocarcinoma in the English literature. Five of these
were esophageal hepatoid adenocarcinomas [13e17] and
the others were designated AFP-producing adenocarci-
nomas [18e21] (summarized in Table 1). Similar to hepatoid
carcinoma in other anatomical sites, hepatoid adenocarci-
noma in the esophagus frequently metastasizes in the liver
and usually pursues a poor clinical course. Most cases were
treated with adjuvant chemotherapy with cisplatin plus 5-
fluorouracil as first-line. The results of this, however,
were mostly disappointing. Chiba et al. reported a case of
esophageal hepatoid adenocarcinoma with multiple liver
metastases that was treated with a combination of pacli-
taxel and cisplatin as the second regimen. The initial
response was partially effective; however, the patient died
due to gastrointestinal bleeding 14 months after the initial
operation [15]. In contrast, non-hepatoid adenocarcinoma
may not be related to Barrett’s esophagus and the clinical
outcomes may differ [20]. However, the small number of
cases reported to date makes it difficult to identify any
definite trends.
In our case, liver function impairment and increasing
AFP caused confusion as to the origin of the site of
malignancy. Upper endoscope biopsy failed to prove AFP-
positive this may be due to the small biopsy specimen
taken. Focal positive of AFP-producing adenocarcinoma
showed the heterogeneous character of tumor growth and
cell type. No obvious presentation of Barrett’s esophagus
was noted and histological examination of the specimen
removed during the operation did not show intestinal
metaplasia in the surrounding tissue, which is character-
istic for Barrett’s esophagus. We therefore believed that
our patient had a case of AFP-producing adenocarcinoma
similar to the case reported by Kobayashi et al [20]. The
clinical outcome appears to be better than that of esoph-
ageal hepatoid adenocarcinoma. As in this case with AFP-
producing adenomcarcinoma without coexisting Barret’s
esophagus, the levels of AFP could be used as therapeutic
markers.(AFP)-producing carcinoma.
Outcome Metastasis Reporter
ed, 2m Liver, lung Motoyama, T
ed, 4m Liver Tanigawa, H
ed, 14m Liver Chiba, N
Liver Atiq, M
ive at 2m* d Kuroda, N
ed, 4m Liver, lung, spleen, LN Sawada, H
ed, 2m Liver, LN Shimakawa, T
ed, 67m Pleura, LN Kobayashi, N
ive at 6m# d Kawai, H
ths. BE Z Barrett’s esophagus; LN Z lymph node metastasis.
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